Pages that link to "Q40070617"
Jump to navigation
Jump to search
The following pages link to Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma (Q40070617):
Displaying 50 items.
- Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents (Q21198868) (← links)
- Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor (Q26747768) (← links)
- DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics (Q26749421) (← links)
- Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential (Q26753019) (← links)
- Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas (Q26774768) (← links)
- Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications (Q26853394) (← links)
- Trials with 'epigenetic' drugs: an update (Q27000542) (← links)
- Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management (Q27024076) (← links)
- Predicting response to epigenetic therapy (Q27027751) (← links)
- Altered histone modifications in gliomas (Q27027924) (← links)
- Metalloprotein–Inhibitor Binding: Human Carbonic Anhydrase II as a Model for Probing Metal–Ligand Interactions in a Metalloprotein Active Site (Q27678293) (← links)
- Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy (Q28082536) (← links)
- Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia (Q28385690) (← links)
- Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression (Q28743074) (← links)
- Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives (Q30570945) (← links)
- Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data (Q30936712) (← links)
- Clinical Toxicities of Histone Deacetylase Inhibitors (Q31135325) (← links)
- Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma (Q33386623) (← links)
- Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. (Q33390876) (← links)
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma (Q33394324) (← links)
- A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors (Q33394863) (← links)
- Panobinostat in lymphoid and myeloid malignancies (Q33408889) (← links)
- A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group (Q33409579) (← links)
- A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma (Q33410997) (← links)
- Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial (Q33428575) (← links)
- Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma (Q33726989) (← links)
- Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. (Q33873844) (← links)
- The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression (Q33934350) (← links)
- Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor (Q33943388) (← links)
- New insights into the treatment of multiple myeloma with histone deacetylase inhibitors (Q34224278) (← links)
- VPA response in SMA is suppressed by the fatty acid translocase CD36. (Q34306857) (← links)
- Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies (Q34399444) (← links)
- Targeting histone deacetyalses in the treatment of B- and T-cell malignancies (Q34414452) (← links)
- Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? (Q34417159) (← links)
- Epigenetic drugs against cancer: an evolving landscape (Q34431964) (← links)
- Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma (Q34434810) (← links)
- Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma (Q34441748) (← links)
- Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors (Q34658892) (← links)
- New Strategies in Peripheral T-Cell Lymphoma: Understanding Tumor Biology and Developing Novel Therapies (Q34683488) (← links)
- Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts (Q34805096) (← links)
- Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy (Q34890457) (← links)
- LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway (Q34952741) (← links)
- Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"? (Q35001132) (← links)
- Interpreting clinical assays for histone deacetylase inhibitors (Q35003657) (← links)
- Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) (Q35022833) (← links)
- Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy (Q35108007) (← links)
- Follow-up of patients with mycosis fungoides after interferon α2b treatment failure (Q35620524) (← links)
- Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review (Q35633420) (← links)
- Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours (Q35653852) (← links)
- Romidepsin in the treatment of cutaneous T-cell lymphoma (Q35683831) (← links)